Background: the validity of conclusions from observational studies depends on decisions regarding design, analysis, data quality, and implementation. through sensitivity analyses, we explored the impact of such decisions on balance control and risk estimates. Methods: Using as a template the Mini-Sentinel protocol for the active surveillance of acute myocardial infarction (Mi) in association with use of antidiabetic agents, we defined cohorts of new users of metformin and second-generation sulfonylureas, baseline covariates and acute Mi events using three combinations of washout and baseline periods. Using propensity-score matching, we assessed balance control and risk estimates using cumulative data for matching all patients compared with not rematching prior matches in quarterly analyses over the follow-up period. Results: A longer washout period increased the confidence in newuser status, but at the expense of sample size; a longer baseline period improved capture of covariates related to pre-existing chronic conditions. When all patients were matched each quarter, balance was improved and risk estimates were more robust, especially in the later quarters. Conclusions: Durations of washout and baseline periods influence the likelihood of new-user status and sample size. Matching all patients tends to result in better covariate balance than matching only new patients. Decisions regarding the durations of washout and baseline periods depend on the specific research question and availability of longitudinal patient data within the database. this paper demonstrates the importance and utility of sensitivity analysis of methods for evaluating the robustness of results in observational studies. (Epidemiology 2015;26: 130-132) T he validity of conclusions from observational studies depends largely on the details of design and analysis, about which investigators must make many decisions, including the following: patient selection; definitions of baseline, covariates, exposure, follow-up, and outcomes; and statistical methods. extensive experiments from the observational Medical outcomes partnership 1 show that results are highly sensitive to these decisions. 2 in this report, we explore the sensitivity of risk estimates and covariate balance to a set of design and analysis decisions, using a realistic example in an electronic medical records database.
METHODS
the Mini-Sentinel project was initiated by the food and Drug Administration (fDA) in 2008 to create a national electronic system for monitoring the safety of fDA-regulated medical products. Hence, we used as a template the Mini-Sentinel protocol for the active surveillance of acute myocardial infarction (Mi) in association with use of antidiabetic agents 3, 4 (henceforth, "the protocol"; see fireman et al 3 for a concise description or Selby et al 4 for details). We applied the newuser design, eligibility, covariate, and acute Mi definitions as in the protocol but compared metformin and second-generation sulfonylureas. We also excluded users of first-generation sulfonylureas.
Although there are published results indicating an elevated risk of sulfonylureas compared with metformin, 5, 6 the effect sizes are small (hazard ratios around 1.2) and the sample size is huge (253,690); thus, residual confounding could explain results. 7, 8 As there is no overwhelming evidence to suggest differential risk, we take the null hypothesis of no difference as true.
New-user Cohort Selection
We identified new users of metformin and sulfonylureas between 1 regenstrief institute's database in a Common Data Model format, 9 de-identified, and transformed from health care data from the indiana Network for patient Care. the first date of a patient's use of a target drug in the regenstrief Common Data Model was taken as the index date. prescription intervals of drugs with the same ingredient were combined into 1 interval if gaps between them did not exceed 30 days. A patient was deemed a "new user" if the interval between the start of a patient's observation in the database and his/her index date was at least a specified number of days (washout). patients with any exposure to metformin or sulfonylureas during washout were excluded. We examined 2 washout intervals: 183 and 365 days.
follow-up began on the index date and continued for as long as the patient continued to be under observation and using the drug of interest.
Eligibility, Covariate, and Outcome Definitions
We examined 2 baselines, 183 and 365 days before index exposure (the latter per protocol). 4 eligibility criteria and baseline covariates were coded according to international Classification of Diseases, 9th edition, Clinical Modification (iCD-9-CM) diagnosis or procedure codes, temporal requirements for their appearance relative to cohort entry, utilization of health care, and medication classes per protocol. 4 Acute Mi was defined as iCD-9-CM hospital principal discharge codes 410.x0 and 410.x1 or deaths occurring within 1 day of an emergency department visit for acute ischemic heart disease (iCD-9-CM codes: 410.x0, 410.x1, 411.1, 411.8, 413.x). patients with acute Mi in the 60 days before the index date were excluded per protocol.
We formed 3 datasets of new users by using these combinations (washout, 365 days; baseline, 183 days); (washout, 365 days; baseline, 365 days); and (washout, 183 days; baseline, 183 days).
Analysis
the propensity score is defined as the probability of being assigned to sulfonylureas conditional on the baseline covariates. the propensity score was derived by fitting separate logistic regression models of exposure to cumulative data for patients with and without prior cardiovascular disease (CVD). 4 propensity-score estimation began once each exposure group had at least 300 patients within each prior CVD stratum, and was updated on the entire cumulative data at each subsequent quarter. 4 patients were matched 1-to-1 by propensity score within a caliper (percent of the standard deviation of propensity-score logit) and exactly on prior CVD status, year, and quarter of index exposure. We explored 2 matching strategies with 2 calipers (10% and 25%): (1) the protocol strategy (emulating an intent-to-treat analysis in a randomized clinical trial), in which only patients new to the cohort were matched with the updated propensity score and pairs formed from previous quarters remained, and (2) an alternative, in which all patients in the cumulative data were matched using the updated propensity score. Matching was performed using SAS macro "gmatch" (Mayo Clinic, rochester, MN). 10 We examined covariate balance for each set of design and analysis decisions by calculating the standardized mean difference 11 and are the group means of metformin and sulfonylureas, respectively, and s M and s S are the respective standard deviations. We also plotted covariates' standardized mean distances for the full cohort and for matched data, by exposure, matching method, and caliper.
Acute Mi hazard ratios of sulfonylureas relative to metformin were obtained for each set of design and analysis decisions using the stratified Cox proportional hazard model, with strata defined by year and quarter of index exposure and prior CVD status in the propensity-score-matched data. 4 to maintain an overall alpha of 0.05 across 10 planned sequential analyses, the protocol 4 required a 1-tailed significance level of 0.0144 to identify a potential signal at each quarterly analysis.
RESULTS
extending washout from 183 to 365 days reduced the number of "new" users by 1745, from 27,420 to 25,675 patients. A longer baseline period improved capture of covariates. Analyses with a 365-day washout had the same number of new users. However, a 365-day instead of 183-day baseline identified 78 more patients with gestational diabetes for exclusion; more smokers (5% vs. 3% for metformin and 7% vs. 5% for sulfonylureas); and more patients with prior CVD (15% vs. 10% for metformin and 29% vs. 21% for sulfonylureas). the overlap between the propensity-score distributions for metformin and sulfonylureas in quarterly cumulative data appeared to be sufficient for relative risk estimation.
propensity-score matching reduced notable imbalances in baseline age, hospitalization, number of medications, chronic obstructive pulmonary disease, hypertension, obesity, use of specific medications (beta-blockers, loop-diuretics, or thiazolidinediones), other heart disease, and other ischemic heart disease (etable 1; http://links.lww.com/eDe/A851). the balance appeared comparable between the two matching methods, although matching all patients tended to produce better balance in most cases, and especially in later quarters (efigure 1; http://links.lww.com/eDe/A851). Calipers 10% and 25% did not show any marked differences in covariate balance. Balance was better in patients without prior CVD than in patients with prior CVD, possibly due to the greater sample size. in contrast, the approach of matching only new patients had higher variability, which did not abate as sample size increased over time.
Hazard ratios of sulfonylureas versus metformin with 97.12% (1 -2 × 0.0144) confidence intervals (Cis) along surveillance time are calculated (efigure 2; http://links. lww.com/eDe/A851). for analyses with a 365-day washout and a 183-day baseline, risk estimates from the approach of matching only new patients produced potential signals on 30 June 2009 and 30 September 2009 for both calipers, whereas risk estimates from the approach of matching all patients signaled on 30 September 2009 only for caliper 25%. for analyses with 365 days for both washout and baseline, all Cis contain the null value of 1 and thus no signals were generated. for analyses with 183-day washout and baseline, risk estimates from the approach of matching only new patients produced potential signals on 30 September 2009 for caliper 10%, and on 30 June 2009 and 30 September 2009 for caliper 25%, whereas risk estimates from the approach of matching all patients signaled on 30 June 2009 for caliper 25% only.
DISCUSSION
Although we adopted a new-user design to simulate randomized studies, we do not have a closed system in the U.S. that covers patients' care for their lifetime, thus entailing compromises in the execution of the design: we could only require a limited nonexposure period in a person's observed past. increasing the washout duration would intuitively enhance confidence in new-user status and allow longer baseline to better capture covariates, though at the price of a reduced sample size. the sample size was reduced by 6.4% when we extended the washout from 183 to 365 days. prevalence of prior CVD was underestimated by 13% using 183-day baseline, delaying the start of surveillance by 6 months because the requirement of 300 patients with prior CVD was not met.
Among the washout-baseline combinations we examined, we think that using 365 days for both is the most appropriate for this example in regenstrief Common Data Model. extending washout-baseline periods could result in too small a sample to investigate a rare outcome of acute Mi in regenstrief Common Data Model (etable 2; http://links. lww.com/eDe/A851). Although longer baseline periods will capture more covariates, these covariates may be less important with respect to their influence on the outcomes as compared to those captured more proximal to the index date.
Matching all patients with updated propensity score tended to produce better covariate balance than matching new patients only (whereas the latter requires less computing), possibly because propensity score was estimated with increasing accuracy and precision as data accumulate.
the Cis of hazard ratios from analyses with 365-day washout and baseline periods included 1.0, regardless of other analysis decisions. With either period being shorter (183 days), 7 Cis based on the approach of matching only new patients had lower limits above 1.0, whereas only 2 Cis based on the approach of matching all patients had lower limits above 1.0. With 183-day intervals, we tended to see more "significant" results although fewer with matching all patients compared with matching only new patients.
in conclusion, we here demonstrated the importance of sensitivity analysis of method decisions in evaluating the robustness of results in electronic medical records studies. 12 Decisions on design and analyses need careful deliberation depending on the research question, the database(s), and the rarity of both outcome and exposures of interest.
